Recent developments in antiplatelet therapy after percutaneus coronary intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is essential for patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).
• Stent implantation during PCI aims to maintain arterial patency but carries a risk of stent thrombosis (ST) up to one year post-procedure.
• Current standard treatment involves combining aspirin with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor).

Purpose of the Study:

• To review the characteristics of P2Y12 antagonists.
• To evaluate current and future clinical guidelines for antiplatelet therapy in the context of PCI with or without stenting.

Main Methods:

• Literature review of P2Y12 antagonist properties.
• Analysis of current and emerging clinical guidelines for antiplatelet therapy post-PCI.

Main Results:

• P2Y12 inhibitors exhibit distinct pharmacological profiles influencing their efficacy and safety.
• Guidelines increasingly emphasize tailored DAPT strategies based on patient risk profiles and procedural characteristics.

Conclusions:

• Understanding P2Y12 antagonist characteristics is key to optimizing antiplatelet therapy.
• Future guidelines will likely refine DAPT duration and intensity to balance ischemic and bleeding risks in PCI patients.